PDGFR-beta Inhibitors
15 drugsAbout PDGFR-beta
Platelet-derived growth factor receptor beta (PDGFR-beta) is a receptor tyrosine kinase involved in cell signaling pathways that regulate cell growth, differentiation, and survival.
PDGFR-beta is a drug target because dysregulation of cell growth contributes to disease; however, there is currently no genetic evidence directly linking PDGFR-beta to specific diseases.
One FDA-approved drug, STIVARGA (Bayer), targets PDGFR-beta; it is a small molecule used in the 'other' therapeutic area category.
PDGFR-beta Genetic Evidence Strong
There is no genetic evidence data available for PDGFR-beta.
Lack of genetic support suggests higher risk in drug development; consider biomarker strategies.
Evidence Across Diseases
10 totalGWAS and other genetic studies link PDGFRB to 10 diseases.
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for PDGFRB colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top PDGFR-beta Drugs
Bayer is the only company with an approved drug targeting PDGFR-beta.
Low competition offers an opportunity for new entrants, but also indicates potential challenges.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| STIVARGA | Bayer | 2012 | 3 |
| SUNITINIB MALATE | Dr. Reddy's | 2021 | 3 |
| SORAFENIB TOSYLATE | YABAO PHARM | 2020 | 3 |
| NEXAVAR | Bayer | 2005 | 3 |
| DASATINIB | Teva | 2016 | 2 |
| VOTRIENT | Novartis | 2009 | 2 |
| GAVRETO | RIGEL PHARMS | 2020 | 2 |
| PAZOPANIB HYDROCHLORIDE | EUGIA PHARMA | 2023 | 2 |
| SPRYCEL | Bristol-Myers Squibb | 2006 | 2 |
| PHYRAGO | HANDA THERAP | 2023 | 2 |
| FOTIVDA | AVEO PHARMS | 2021 | 1 |
| QINLOCK | DECIPHERA PHARMS | 2020 | 1 |
PDGFR-beta Drug Modality Landscape
Modalities
Routes of Administration
PDGFR-beta is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies to differentiate from existing therapies.
PDGFR-beta Clinical Trials 1,232 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PDGFR-beta. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 430 | 274 | 100 | 54 | 73% |
| Phase 2 | 637 | 335 | 165 | 135 | 67% |
| Phase 3 | 136 | 76 | 21 | 39 | 78% |
| Phase 4 | 29 | 18 | 3 | 8 | 86% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
5 Phase 3 trials testing approved PDGFR-beta drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PDGFR-beta. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PDGFR-beta Drug Approval Timeline (2005 - 2023)
The first and only drug, STIVARGA, was approved in 2012.
The approval timeline suggests a saturated market; new approaches are needed.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 13 companies competing
- • Market share by company
Full Drug Portfolio
- • All 15 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 15-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 454 (105 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PDGFR-beta. A trial counts if an approved drug acting on PDGFR-beta is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.